Alessandro Riva Sells 212 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Director Alessandro Riva sold 212 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $309.51, for a total transaction of $65,616.12. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Price Performance

NASDAQ ONC traded down $2.43 during trading hours on Wednesday, reaching $300.01. The company’s stock had a trading volume of 159,041 shares, compared to its average volume of 252,436. The firm has a market capitalization of $32.92 billion, a price-to-earnings ratio of 67.12 and a beta of 0.50. The company’s 50-day moving average is $301.85 and its two-hundred day moving average is $321.12. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $235.57 and a 1-year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion during the quarter. On average, equities analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

A number of hedge funds have recently added to or reduced their stakes in the business. EFG International AG purchased a new position in BeOne Medicines in the 4th quarter valued at approximately $25,000. Leonteq Securities AG purchased a new stake in shares of BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. acquired a new stake in shares of BeOne Medicines in the second quarter valued at $35,000. CWM LLC boosted its holdings in BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC purchased a new position in BeOne Medicines in the fourth quarter valued at $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wolfe Research started coverage on shares of BeOne Medicines in a report on Friday, March 27th. They issued an “outperform” rating and a $340.00 price objective on the stock. Wells Fargo & Company initiated coverage on BeOne Medicines in a research report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Truist Financial reaffirmed a “buy” rating and issued a $413.00 price objective (up from $411.00) on shares of BeOne Medicines in a research note on Thursday, May 7th. Finally, Leerink Partners increased their target price on BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, BeOne Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $389.15.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.